RELMADA THERAPEUTICS, INC.
RLMD$19M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCORAL GABLES17 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
9dMarket Overview
Stock performance and key metrics
RLMD News
Catalyst Timeline
2 upcoming, 0 past
Phase 3Next
Phase 3 Results - RESCUE
Jun 30, 2026AI-detected
Relmada Therapeutics targets mid-2026 initiation of a Phase 3 RESCUE trial, supported by $234M in cash runway extending through 2029.
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Drug Pipeline
REL-1017
Depressive Disorder, Major
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REL-1017 | Phase 3 | Depressive Disorder, Major | - | - |
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply